Browse key industry insights from the report “PEGylated Drugs Market Size, Industry
Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Italy, France, China,
India, Japan, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia),
Application Development Potential, Price Trends, Competitive Market Share & Forecast,
2017 – 2024” in detail along with the table of contents:
https://www.gminsights.com/industry-analysis/pegylated-drugs-market
Different proteins such as mAbs, colony stimulating factors, recombinant factor vii,
interferons and many more can be coupled with PEG molecule. PEGylated interferon is a
class of drugs that includes Peginterferon alfa 2a and alfa 2b. These are FDA approved
and used for the treatment of hepatitis C and in some cases for hepatitis B.
The process is primarily used by pharmaceutical and biotechnology companies,
research institutes and contract research organization. In chronic conditions, frequent
dosing can reduce patient’s compliance to the treatment. Research institute are working
relentlessly to reduce the dose using PEGylation techniques. Its therapeutic agents are
expanding clinical pipelines for many biotech companies as the technique is now being
applied to peptides, aptamers, and smaller molecules.
As per center for disease control and prevention, in U.S. around 400 babies suffer from
hemophilia each year. Demand for long acting drugs with extended half-life to treat such
diseases is increasing in the region. The increased adoption of protein based drugs is
expected to drive the U.S. market over forecast period.
Asia pacific is predicted to show significant growth due to rising prevalence of chronic
diseases like cancer and arthritis. For instance, in China cancer caused 2.8 million
deaths and 4.3 million new cases were diagnosed. The high prevalence of such diseases
will boost the regional revenue share over the forecast timeframe.
Companies operating in business include Thermo Fisher Scientific, Merck, Johnson &
Johnson, Creative PEGworks, NOF, Quanta BioDesign Celares Biomatrik, and Iris Biotech
Laysan Bio. To gain competitive advantage companies are adopting strategies like
mergers and acquisitions, partnerships, collaborations, and geographical expansions.
For instance, in June 2015, Merck entered into a collaboration with Celares, a German
based firm involved in the business of PEGylation and chemical modification of
biopharmaceuticals. The collaboration expanded Merck’s product of portfolio of
functionalized products.
2 | Page